Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  aminolevulinic acid hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 25 for your search:
Start Over
Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NL38127, NCT01491711
Photodynamic Therapy for Oral Precursor Lesions
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010_MuSH, NCT01497951
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
Phase: Phase III
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP0108, NCT02137785
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALA-BCC-CT008, 2013-003241-42, NCT02144077
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: COZ-SIU 10-002-1, NCT01128218
Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: JointAPHSHC, 2014-002746-50, NCT02367547
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE1305, P30CA043703, NCT00752323
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 104974, NCT00961090
Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 72
Sponsor: Other
Protocol IDs: 10101, NCT01116661
A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ALA 11.07, NCT01351519
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: IRB00051663, WCI1999-11, NCT01445691
Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: TASMC-11-JB-558-CTIL, NCT01898416
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + ALA Photodynamic Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP0109, NCT02239679
Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CASE2614, NCI-2014-02037, P30CA043703, NCT02258243
MUSE Study of Levulan Kerastick
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP0110, NCT02281136
Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 to 50
Sponsor: Pharmaceutical / Industry
Protocol IDs: FDZJALA-201409, NCT02304770
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000650536, UPCC-18308, IRB #809093, NCT00978081
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Phase: Phase I
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1140, NCT01502605
Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: PRO 14555, NCT01682811
ALA-induced PpIX Fluorescence During Brain Tumor Resection
Phase: Phase I
Type: Diagnostic
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: DMS 13066, R01NS052274-01A2, NCT02191488
Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)
Phase: No phase specified
Type: Diagnostic
Status: Active
Age: 20 to 70
Sponsor: Other
Protocol IDs: ZU-XYZ-002, NCT01208909
Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery
Phase: No phase specified
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: JohannWGUH_IMAGER, 206/12, NCT01798771
5-ALA in Recurrent Glioma
Phase: No phase specified
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11BN092, NCT02119338
Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome
Phase: No phase specified
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CASE 2614, NCT02157623
Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: Nch1, NCT02379572
Start Over